The ongoing search for novel and improved therapeutics is being driven by the increasing prevalence of antimicrobial resistance, infectious diseases and the continuous emergence of new and existing pathogens.
It has been estimated that the global incidence of deaths from infectious diseases is currently 25%, with an array of environmental, ecological and demographic factors contributing to this rise. Other factors influencing this include the ongoing evolution of viral and microbial variants and the selection of drug-resistant strains.
Cerba Research offers a diverse array of fully integrated clinical laboratory and diagnostic solutions. The company and its solutions are designed to help its customers successfully develop robust treatments and effective vaccines to better manage emerging pathogens.
Cerba Research’s routine testing services are available on a global scale, with its divisions in the Americas, Europe and South Africa offering industry-leading Biosafety Level 3 facilities.
The company’s extensive expertise covers everything from routine testing to sequencing, and its wide-ranging experience places Cerba Research at the forefront of epidemiological surveillance.
By maintaining an acute awareness of regional variations in genotypes, Cerba Research can provide its customers with detailed insight into the spread of pathogens, supporting the development of optimal therapeutic strategies.
So far, the company has screened 17,973 patients in 63 countries, thanks to its access to 1,550 sites.
Customized, flexible and rapid response
Cerba Research is continuing to invest in providing in its network of scientific experts across five continents and its integrated, wide-ranging selection of state-of-the-art bacteriology, virology and parasitology testing tools.
Ongoing partnerships with key experts and decision-makers throughout the industry are central to ensuring an immediate response to emerging infectious threats. By leveraging these collaborative networks, Cerba Research is able to develop new tests in very short time frames.
The company offers an array of fast and secure diagnostic solutions. Cerba can also adjust its range of assays and technology transfers to meet the needs of a fast-moving market and accommodate seasonal changes.
A comprehensive range of techniques is available, ideal for ensuring the optimal detection, identification, characterization and quantification of pathogens. These include:
- Culture and microscopy
- Molecular pathogen detection and sequencing
- Mass spectrometry-based techniques to facilitate rapid bacterial ID
- Inhibition and neutralization assays
The company also has broad experience in detecting:
- Respiratory viruses, including influenza and RSV
- Arboviruses, including Zika and dengue
- Hepatitis viruses
- HIV and HPV viruses
- Bacteria, including TB and C. difficile
- Parasites, including malaria
- Fungal infections
About Cerba Research
For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.
From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.